Tirofiban for no-reflow in heart attack patients
Part of Heart & circulation clinical trials.
This trial tests if a drug called tirofiban, given directly into the heart artery, can prevent or treat no-reflow (when blood doesn't flow well even after the blockage is opened) in people having a severe heart attack known as STEMI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are having a STEMI heart attack (a specific type where the ECG shows ST-segment elevation or a new bundle branch block).
- You have not received a clot-busting (thrombolytic) drug in the last 24 hours.
- You do not have cancer, a low platelet count, end-stage liver disease, cardiogenic shock, or severe kidney disease.
- You can safely take the drug tirofiban (no known allergies or bleeding risks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
This trial tests whether giving a medication called tirofiban directly into the artery (intra-arterially) after a successful clot removal can improve recovery after a stroke. Tirofiban helps prevent new clots from forming, which may reduce the chance of another stroke.
This trial tests a clot-busting drug (TNK) versus a blood thinner (tirofiban) in people having a major heart attack with a large clot. If you qualify, you would get the medicine directly into your heart artery through a thin tube to see which works better.
This trial is testing a new way to quickly measure the level of a blood thinner (tirofiban) in the blood of people having a heart attack. It aims to make sure the dose is right and safe for each patient.
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
Hear when a new STEMI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.